US20200397985A1 - Devices and methods for on-line whole blood treatment - Google Patents
Devices and methods for on-line whole blood treatment Download PDFInfo
- Publication number
- US20200397985A1 US20200397985A1 US16/918,494 US202016918494A US2020397985A1 US 20200397985 A1 US20200397985 A1 US 20200397985A1 US 202016918494 A US202016918494 A US 202016918494A US 2020397985 A1 US2020397985 A1 US 2020397985A1
- Authority
- US
- United States
- Prior art keywords
- whole blood
- conduit
- channel
- target compound
- crp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 81
- 239000008280 blood Substances 0.000 title claims abstract description 81
- 238000011282 treatment Methods 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 43
- 108090001007 Interleukin-8 Proteins 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 13
- 108091023037 Aptamer Proteins 0.000 claims description 9
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 9
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 231100000765 toxin Toxicity 0.000 claims description 9
- 239000003053 toxin Substances 0.000 claims description 9
- 108700012359 toxins Proteins 0.000 claims description 9
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 239000012491 analyte Substances 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 238000002638 palliative care Methods 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 abstract description 33
- 230000008929 regeneration Effects 0.000 abstract description 20
- 238000011069 regeneration method Methods 0.000 abstract description 20
- 102000004890 Interleukin-8 Human genes 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 230000027455 binding Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000009467 reduction Effects 0.000 description 11
- 238000007789 sealing Methods 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000003446 ligand Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 229940125644 antibody drug Drugs 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002594 sorbent Substances 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 108091027757 Deoxyribozyme Proteins 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102100021010 Nucleolin Human genes 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108010044762 nucleolin Proteins 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- -1 CD86 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 208000021251 Methanol poisoning Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 1
- 108030001722 Tentoxilysin Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229950009925 atacicept Drugs 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000037801 influenza A (H1N1) Diseases 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 108010038415 interleukin-8 receptors Proteins 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/165—Filtering accessories, e.g. blood filters, filters for infusion liquids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
- B01D15/1892—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns the sorbent material moving as a whole, e.g. continuous annular chromatography, true moving beds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
- B01D15/203—Equilibration or regeneration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3823—Affinity chromatography of other types, e.g. avidin, streptavidin, biotin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0445—Proteins
- A61M2202/0447—Glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/049—Toxic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/203—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/20—Pathogenic agents
- A61M2202/206—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/10—General characteristics of the apparatus with powered movement mechanisms
- A61M2205/103—General characteristics of the apparatus with powered movement mechanisms rotating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/10—General characteristics of the apparatus with powered movement mechanisms
- A61M2205/106—General characteristics of the apparatus with powered movement mechanisms reciprocating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3344—Measuring or controlling pressure at the body treatment site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/14—Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/08—Supports for equipment
- A61M2209/088—Supports for equipment on the body
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2215/00—Separating processes involving the treatment of liquids with adsorbents
- B01D2215/02—Separating processes involving the treatment of liquids with adsorbents with moving adsorbents
- B01D2215/022—Physically moving the adsorbent as a whole, e.g. belts, discs or sheets
Definitions
- the field of the invention is treatment of whole blood, especially as it relates to in vivo continuous removal of one or more components contained in whole blood.
- Removal of various undesirable components from whole blood is well known and often includes ex vivo separation of cellular components (e.g., centrifugation or filtration) to obtain a cell-free fluid that is then processed, typically using affinity media and/or enzymatic treatment. While such treatment is standard practice in many instances, hemolysis is often a problem. Still more disadvantageously, such known treatment typically requires relatively large equipment and is therefore impractical in ambulatory use.
- the present inventive subject matter is directed to diagnostic and therapeutic devices in which whole blood is passed through one or more channels of a rotating or reciprocating element wherein the channels comprise an affinity agent to allow specific binding of a target compound to the channel. Due to the rotating or reciprocating motion of the element, the channel can be moved into and out of fluid communication with the circulatory system of a mammal such that the affinity agent binds the target compound when the channel is in fluid communication with the circulatory system and such that bound target antigen can be removed from the affinity agent when the channel is removed from the fluid communication with the circulatory system and in fluid communication with a regeneration circuit.
- the rotating or reciprocating element has multiple channels and is configured as a rotating wheel, and multiple conduits are separately provided to the channels in the wheel to allow concurrent adsorption of the target compound to one channel while regenerating the affinity agent in another channel.
- the element may also be configured as an Archimedean screw or a reciprocating piston. Consequently, it should be recognized a target compound can be continuously removed from the blood stream on-line and in vivo as such devices and methods allow for multiple passes of whole blood through the device without saturating the affinity agent.
- contemplated devices will therefore include a first conduit, a second conduit, and a rotating or reciprocating element having a channel, wherein the first and second conduits are fluidly coupled to the rotating or reciprocating element such that the channel is fluidly continuous with the first conduit when the channel is fluidly discontinuous with the second conduit, and such that the channel is fluidly discontinuous with the first conduit when the channel is fluidly continuous with the second conduit.
- the first conduit is preferably configured to receive whole blood (directly from the circulation in an on-line mode, or indirectly, via blood collection bag or other implement), and the second conduit is preferably configured to receive a regeneration fluid (typically from a reservoir or device that prepares the regeneration fluid in situ).
- the channel will have a surface that is modified with an affinity agent (most typically an antibody or antibody fragment, a nucleic acid or nucleic acid analog, a lectin, etc.) at a concentration effective to allow removal of a target compound from whole blood, wherein the target compound is capable of binding with high specificity and affinity to the affinity agent.
- an affinity agent most typically an antibody or antibody fragment, a nucleic acid or nucleic acid analog, a lectin, etc.
- FIG. 1A illustrates a whole blood treatment device including a wheel.
- FIG. 1B illustrates a whole blood treatment device including an Archimedean screw.
- FIG. 1C illustrates a whole blood treatment device including a reciprocating piston.
- FIG. 1A depicts an exemplary device in which the rotating or reciprocating element is configured as a wheel having a plurality of conduits extending through the wheel.
- the wheel is preferably rotatably coupled to at least two conduits, which are here indicated as half-pipes with abutting surfaces to so form a cylindrical structure.
- the wheel is disposed in the middle of the conduits such that flow of whole blood enters the upper conduit at the site marked ‘whole blood inlet’, passes through the upper three channels that are coated with an antibody (e.g., specific against IL-8), and continues to flow through the upper half-pipe to exit at the site marked ‘whole blood outlet’. During this pass, target compounds will bind to the affinity agents.
- an antibody e.g., specific against IL-8
- flow of regeneration fluid enters the lower conduit at the site marked ‘regen fluid inlet’, passes through the lower three channels and causes the bound target compounds to elute into the regeneration fluid, which flows through and exits the lower half-pipe to leave the pipe at the site marked ‘regen fluid outlet’.
- the wheel will rotate during operation, preferably at a speed that will allow saturation of the affinity agents with the target compound during the presence of the channel in the upper half-pipe. Once saturated, and due to the preferably continuous rotation of the wheel, the channel with the saturated affinity agents will enter the lower half-pipe and is then exposed to the regeneration fluid for regeneration of the affinity agent. Once regenerated, and due to the preferably continuous rotation of the wheel, the channel with the regenerated affinity agents will enter the lower half-pipe and is once again available for a new cycle of binding and regeneration.
- the rotating or reciprocating element is configured as a Archimedean screw that fittingly extends through the length of a cylindrical main pipe.
- two fluid conduits join the main pipe in a manner such that (a) fluid entering on one branch of the main pipe is pumped along the pipe and exits one of the two joining conduits, and (b) fluid entering the other of the two joining conduits is pumped into and along the other branch and exits the other branch.
- the channel is formed by the helical groove of the screw and is also coated with (or otherwise coupled to) an affinity agent.
- whole blood flows through one branch of the main pipe for adsorption of the target compound, while at the same time regeneration fluid flows through the other main branch for regeneration of the affinity agent.
- Flow of the whole blood and the regeneration fluid is then alternatingly controlled such that when the affinity agents are saturated in one branch, whole blood flow is routed to the other branch that is now regenerated.
- Regeneration fluid is then routed to the saturated channel to regenerate the binding surface.
- the operational mode between binding and regeneration is switched by switching flow though the device.
- the moving element may also be configured as a reciprocating piston with one or more channels extending through the piston as exemplarily illustrated in FIG. 1C .
- the piston has a plurality of channels where two channels are concurrently employed for binding and absorption.
- the regenerated channel is moved into the flow of whole blood as the binding channel is saturated.
- FIG. 1C shows an additional channel which may be employed for measurement of an analyte and/or dispensation of a pharmaceutical agent.
- contemplated methods include a step of moving the whole blood through a channel in a rotating or reciprocating element while the channel is fluidly coupled to a first conduit that contains the whole blood, wherein the channel comprises a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood.
- the rotating or reciprocating element is moved into a position such that the channel is fluidly disconnected from the first conduit and fluidly connected with a second conduit, and in yet another step, the target compound is eluted from the surface while the channel is fluidly connected with the second conduit.
- the rotating or reciprocating element is then further moved into a position such that the channel is fluidly connected with the first conduit and fluidly disconnected with the second conduit.
- a whole blood treatment device may include a first conduit, a sealing area, and a rotating or reciprocating element having a channel, wherein the first conduit is fluidly coupled to the rotating or reciprocating element such that the channel is fluidly continuous with the first conduit when the channel is fluidly discontinuous with the sealing area, and such that the channel is fluidly discontinuous with the first conduit when the channel is fluidly continuous with the sealing area.
- the first conduit is configured to receive whole blood
- the sealing area is configured to allow flow-less incubation of the whole blood in the channel when the channel is fluidly continuous with the sealing area.
- a volume of whole blood is captured in the channel while the channel is in contact with the sealing area to so allow binding of a target compound from an essentially non-moving or non-flowing volume of whole blood.
- Such incubation is considered to improve binding efficiency, especially where the volume-to-surface ratio is relatively high.
- the channel will include a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood.
- the rotating or reciprocating element is disposable and/or user-replaceable, and/or the channel is configured as a replaceable cylinder.
- Typical non-regenerating devices are similar to the devices shown in FIG. 1A-1C , however, will not provide second conduits for regeneration fluid.
- the second conduit in the device of FIG. 1 is entirely omitted and a sealing plate or other sealing implement will seal off the lower conduit.
- the Archimedean screw configuration of FIG. 1B is simplified in that the perpendicular in- and outlet ports can be omitted. In such case, it is generally preferred that two linear conduits will have two independent Archimedean screws with one screw operating while the other screw is not operating and replaceable. Increased incubation time is then achieved by discontinuous rotation, or by addition of a second (third, or higher) screw that operates in a parallel and alternating mode.
- a second (third, or higher) screw that operates in a parallel and alternating mode.
- the device configuration is again simplified by providing one or more flow channels through the reciprocating block. Reciprocating movement of the block will then position a volume of whole blood in a channel between sealing surfaces for a predetermined time to allow longer incubation, and reversal of that movement (or additional forward movement) will then move the treated volume back into circulation.
- contemplated devices are configured to be wearable, and that the reciprocating or rotating element can be readily exchanged, preferably by a non-medical professional (e.g., end user or caretaker).
- the device has a housing that encloses at least partially the element and conduits. Fluid lines from the patient's circulation and/or regeneration fluid are preferably attachable via luer lock or other suitable connector that preferably allows maintaining sterile working conditions.
- the regeneration fluid and other fluids, including wash fluids
- the device may include more than one rotating or reciprocating element and/or that there are more than one type of affinity agent in one or more channels.
- contemplated devices and methods are not limited to those having only two conduits, but any number of conduits are deemed suitable. Additional conduits may be used for measurement of one or more analytes in the whole blood and/or the regeneration fluid, and/or for provision of wash fluids and/or pharmaceutical agent.
- contemplated device may also implement additional functionalities using a flow splitter that may be upstream or downstream, of the wheel (with respect to the flow of the whole blood). The so produced bypass or slipstream can then be treated or analyzed as desired, and fed back to the circulation or be discarded into a typically disposable waste container.
- the conduit may include or may be coupled to a surge compartment to accommodate discontinuous flow and to maintain constant flow rate through the device.
- contemplated devices may have a continuously operating pump, a pump that operates in on-off mode, or no pump at all.
- the whole blood may be driven by an active pump (e.g., peristaltic, piston, etc.), or passively by a blood pressure driven mechanism.
- the reciprocating or rotating element is actuated by a motor or other actuator, preferably in a continuous manner at constant speed.
- the speed of the rotating or reciprocating element may also be variable and/or in an intermittent pattern.
- channels may vary considerably and will predominantly be determined by the desired flow rate of whole blood through the element, the quantity of target compound in the whole blood, and affinity of the target compound. It is generally preferred that the channels are formed to reduce or even entirely avoid turbulent flow. Thus, channels are preferably linear or helical with a larger-than-capillary diameter (e.g., at least 50 micron, more preferably at least 100 micron, and most preferably at least 250 micron). It is further noted that the transition of a channel from blood to regeneration fluid may include a rinse step in the device and/or via a flow loop with one or more valves. Thus, most preferably, loss of whole blood is avoided as the volume of whole blood in the channel may be recycled back to the mammal (e.g., using isotonic fluid as a wash fluid).
- Sealing of the movable element against fluid and blood loss can be achieved in numerous manners well known in the art. For example, rotary seals, rubber lip seals, or bore seals with 0-rings are deemed suitable for use herein. Similarly, press-fit tolerance may be employed to reduce leakage of the channel/conduit interface.
- IL-8/CRP reduction is performed on-line in a continuous manner using a wearable device, such as the device described herein.
- the device can be used to remove other antigens and small molecules from whole blood by passing the blood through channels, which comprise an affinity agent to bind to the target compound.
- IL-8 and CRP levels are elevated in whole blood of a patient undergoing taxane (e.g., paclitaxel or decetaxel) chemotherapy, for example, in the treatment of pancreatic cancer.
- taxane e.g., paclitaxel or decetaxel
- Such treatment may be in combination with other drugs, for example, gemzitabine.
- chemotherapy in such and similar cases is not well tolerated and a significant fraction of patients will discontinue treatment due to the severe side effects.
- IL-8 and CRP levels in patients about to discontinue chemotherapy is well above normal reference ranges, typically at least 25%, and most typically at least 50% above the upper range of normal, and contemplate that continuous reduction of the elevated levels, preferably back to reference range, will increase the level of compliance. It is generally preferred that the continuous treatment will extend over a period of at least 12 hours, more typically at least 24 hours, and most typically over at least 3 days. Thus, and viewed from another perspective, it is contemplated that the reduction of IL-8 and/or CRP will be effected over a period that coincides with at least a portion of time over which elevated levels will be observed without treatment.
- IL-8 and/or CRP are not intended as a treatment modality of the underlying disease, but as a palliative treatment of a condition that is brought about by pharmacological intervention.
- methods presented herein are targeted to improve subjective well-being of a patient, and especially relieve nausea, flu-like symptoms, loss of appetite, and physical and/or metal fatigue.
- contemplated methods may be effective not only in combating side effects of chemotherapy of various neoplastic diseases, but also infectious diseases and especially including viral diseases (and particularly influenza virus, H1N1 flu, SARS, etc.), chronic inflammatory diseases (e.g., COPD, rheumatoid arthritis, inflammatory bowel disease, psoriasis, etc.), atherosclerosis, and acute coronary syndrome.
- viral diseases and particularly influenza virus, H1N1 flu, SARS, etc.
- chronic inflammatory diseases e.g., COPD, rheumatoid arthritis, inflammatory bowel disease, psoriasis, etc.
- atherosclerosis e.g., atherosclerosis, and acute coronary syndrome.
- the chemotherapeutic agent may vary considerably.
- the pharmaceutical treatment will include chemotherapy for various neoplastic diseases, and especially those agents that are known to be associated with an increase in IL-8 and/or CRP.
- contemplated chemotherapies may include administration of one or more of receptor antibodies, alkylating agents, antimetabolites, microtubule inhibitors (and especially taxanes), topoisomerases, and kinase inhibitors.
- contemplated methods may be implemented on an intermittent or continuous basis, and it is generally contemplated that the reduction in IL-8 and/or CRP is performed as long as excessive levels of IL-8 and/or CRP are measured or anticipated.
- IL-8 may be performed in a continuous manner over two days.
- reduction may be performed in a discontinuous manner immediately following administration of the chemotherapeutic agent.
- the elevated levels of IL-8 and/or CRP are, for example, due to a chronic inflammatory condition, continuous reduction in IL-8 and/or CRP may be advisable.
- IL-8 Removal is preferably monitored to achieve a continuous IL-8 and/or CRP level that is within the normal reference range (and in some cases below or slightly above).
- the clinical range of IL-8 is typically between 10-80 pg/ml for a healthy person, and it is typically preferred that reduction of IL-8 is to equal or less than 100 pg/ml, and more preferably to equal or less than 80 pg/ml.
- the clinical normal range for CRP is between 0-5 mg/l for male and 0-8 for female healthy adults, and it is typically preferred that reduction of CRP is to equal or less than 5 mg/1, more preferably to equal or less than 3 mg/l, and most preferably to equal or less than 1 mg/l.
- Reduction of IL-8 and/or CRP is preferably effected via specific antibodies (e.g., HuMab 10F8 for IL-8), or other known IL-8 binders, including glycosaminoglycan (GAG) heparin, protease inhibitor alpha2-macroglobulin, Cyclosporin A, however, engineered binding agents are also deemed suitable, including recombinant IL-8 receptor and fragments thereof.
- specific antibodies e.g., HuMab 10F8 for IL-8
- IL-8 binders including glycosaminoglycan (GAG) heparin, protease inhibitor alpha2-macroglobulin, Cyclosporin A
- GAG glycosaminoglycan
- Cyclosporin A Cyclosporin A
- engineered binding agents are also deemed suitable, including recombinant IL-8 receptor and fragments thereof.
- CRP can be reduced by binding of CRP to one or more types of monoclonal or polyclonal antibodies, Fc receptors (e.g., Fc ⁇ RIIa), etc., and the number of binding agents needed to reduce the IL-8 and/or CRP levels will preferably be chosen such that continuous treatment for at least 2, and more typically 4 consecutive days is possible without patient intervention.
- Fc receptors e.g., Fc ⁇ RIIa
- the device may also be used to target other cellular components and extracellular components, such as proteins, fats and small molecules, and may also be used to target cells.
- the whole blood treatment device can also be used to treat various diseases that are caused by one or more target compounds. Examples of these disease include treating cancer by reducing inhibitory checkpoint molecules or removing cancer cells, autoimmune diseases by reducing inflammatory factors, cardiovascular disease by reducing low-density lipoprotein, metabolic diseases such as diabetes by reducing glucose, viral infection and bacterial infection by reducing the amount of virus, bacteria or associated toxin, and toxin exposure and heavy metal exposure by removing the toxin or heavy metal.
- Such diseases may be treated with the device by determining a target compound that can be removed from the body, and determining an affinity agent that binds to the target compound.
- Antibodies or aptamers suited to binding the selected target compound could be used as the affinity agents, but it is understood that other compounds could also be used.
- Inhibitory checkpoint molecules are secreted by cancer cells to reduce the immune response.
- There are several antibody drugs referred to as immune checkpoint inhibitors or immune checkpoint blockades) that target these inhibitory checkpoint molecules in order to increase the immune response to cancer cells.
- immune checkpoint inhibitors referred to as immune checkpoint blockades
- the whole blood treatment devices pass whole blood through channels with a surface modified with affinity agents, where the inhibitory checkpoint molecules are bound by the affinity agents, and removed from the blood, reducing the concentration of inhibitory checkpoint molecules in the blood.
- inhibitory checkpoint molecules are cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), programmed death-ligand 1 (PD-L1), B7-1, B7-2, FOXP3 + , FOXP3 ⁇ , Treg 17, Trl, Th3, IL-10, and TGF- ⁇ .
- CTL-4 cytotoxic T-lymphocyte associated protein 4
- PD-1 programmed cell death-1
- PD-L1 programmed death-ligand 1
- B7-1, B7-2 programmed death-ligand 1
- FOXP3 + FOXP3 +
- FOXP3 ⁇ Treg 17, Trl, Th3, IL-10
- TGF- ⁇ TGF- ⁇
- antibody drugs that could be used as affinity agents include ipilimumab, ticilimumab, pembrolizumab, atezolizumab and nivolumab, along with many others, as described in Ghirelli et al. (“Targeting
- Inflammatory factors are often reduced using antibody drug treatments. Rather than administering antibodies as drugs, these same antibodies can be used in the channels of the whole blood treatment devices to bind inflammatory factors to reduce the concentration of inflammatory factors in the blood.
- Inflammatory factors may include IL-4, IL-10, TNF ⁇ , IL-17A, IL-17F, CRP, TNF, IL-1 ⁇ , IL-1 ⁇ , IL-5, IL-6, IL-8, IL-12, IL-23, CD2, CD3, CD20, CD22, CD52, CD80, CD86, C5 complement protein, BAFF, APRIL, IgE, ⁇ 4 ⁇ 1 integrin and ⁇ 4 ⁇ 7 integrin.
- IL-17A/F antibodies abatacept, alefacept, alemtuzumab, atacicept, belimumab, canakinumab, eculizumab, epratuzumab, natalizumab, ocrelizumab, ofatumumab, omalizumab, otelixizumab, rituximab, teplizumab, vedolizumab, adalimumab, briakinumab, certolizumab pegol, etanercept, golimumab, infliximab, mepolizumab, reslizumab, tocilizumab and ustekinumab.
- viruses can be targeted using various drugs. However, removing these from the blood, via a whole blood treatment device would reduce unintended side effects.
- the target compounds can include viruses and cells infected with viruses. Examples of viruses include chickenpox, flu (influenza), herpes, human immunodeficiency virus (HIV/AIDS), human papillomavirus (HPV), infectious mononucleosis, mumps, measles, rubella and shingles. Antibodies that bind to these viruses may be used as the affinity agent, and can be prepared by well-known methods.
- Antibodies can be used to treat various cancers. Rather than using antibodies that bind cancer cells as a drug, these antibodies can be used in a channel of a whole blood treatment device. Examples of cancer cells include skin, breast, lung, pancreas, kidney, leukemia, lymphoma, and many other types of cancer. For example, treatment of cancer can be carried out by targeting cells displaying nucleolin on the cell surface. Anti-nucleolin antibodies can bind to the nucleolin on the surface of the cancer cell.
- anti-nucleolin antibodies include p7-1A4 mouse monoclonal antibody, sc-8031 mouse mAb, sc-9893 goat polyclonal Ab (pAb), sc-9892 goat pAb, clone 4E2 mouse mAb, and clone 3G4B2 mouse mAb, which may be used as affinity agents.
- antibody drugs to treat cancer cells which may be used as affinity agents include alemtuzumab, trastuzumab, Ibritumomab tiuxetan, Brentuximab vedotin, Ado-trastuzumab emtansine, denileukin diftitox, and blinatumomab, along with other can be found in American Cancer Society; Monoclonal Antibodies to Treat Cancer (available at www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/monoclonal-antibodies.html). Other drugs may be used to bind cancer cells within the device.
- Heavy metal poisoning may be treated with a whole blood treatment device to reduce the concentration of heavy metals to a safe level.
- Heavy metals may include lead, mercury, arsenic and cadmium. These metals can be bound by an affinity agent such as DNAzyme as described in Zhang et al. (“Metal Ion Sensors Based on DNAzymes and Related DNA Molecules” Annual review of analytical chemistry 2011; 4(1):105-128). Chelating agents could also be used as an affinity agent to bind to the target compounds in the device.
- Alzheimer's disease can be treated with solanezumab. Rather than administering this drug to a patient, a whole blood treatment device can be used to filter target compounds from whole blood, using the antibody as an affinity agent.
- target compounds for Alzheimer's disease include misfolded amyloid beta and tau proteins.
- Bacteria and toxins in the bloodstream can be treated with various drugs. Rather than administering these drugs to a patient, a whole blood treatment device can be used to filter the bacteria or toxins from whole blood.
- toxins which could be target compounds include botulinum toxin produced by Clostridium botulinum, Corynebacterium diphtheriae toxin, produced during life-threatening symptoms of diphtheria, and tetanospasmin produced by Clostridium tetani .
- Antibodies and aptamers may be used as affinity agents for the bacteria or toxins. Such antibodies and aptamers may be prepared by well-known methods.
- cytokines including tumor necrosis factor (TNF) and interleukin 1
- TNF tumor necrosis factor
- interleukin 1 inhibitory checkpoint molecules are also present in increased concentration in the blood of patients with sepsis.
- TNF tumor necrosis factor
- a whole blood treatment device can be used to filter the cytokines or inhibitory checkpoint molecules from whole blood.
- Antibodies and aptamers may be used as affinity agents for the bacteria or toxins.
- Methanol poisoning can be treated by competitive inhibition. Methanol concentration could also be reduced using the whole blood treatment device with affinity agents such as aptamers.
- Heroin overdoses can be treated by various drugs. Rather than administering these drugs, a whole blood treatment device could be used to reduce the concentration of opioids in the blood.
- Antibodies, aptamers or other compounds may be used as affinity agents for the opioids.
- Monoclonal antibodies are usually made by fusing mouse spleen cells immunized with a desired antigen with myeloma cells (B-cell cancer cells, which are known for producing antibodies). The fused cells are transferred to a medium that is selective for fused cells. Several cell cultures are then grown from single parent cells. The antibodies from the different parent cells are then assayed using well-known methods such as ELISA to determine the antibodies ability to bind the antigen.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- External Artificial Organs (AREA)
Abstract
A whole blood treatment device includes a first conduit, a second conduit, and a rotating or reciprocating element having a channel. The first and second conduits are fluidly coupled to the rotating or reciprocating element such that the channel is fluidly continuous with the first conduit when the channel is fluidly discontinuous with the second conduit, and such that the channel is fluidly discontinuous with the first conduit when the channel is fluidly continuous with the second conduit. The first conduit is configured to receive whole blood, and the second conduit is configured to receive a regeneration fluid. The channel comprises a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood.
Description
- The field of the invention is treatment of whole blood, especially as it relates to in vivo continuous removal of one or more components contained in whole blood.
- Removal of various undesirable components from whole blood is well known and often includes ex vivo separation of cellular components (e.g., centrifugation or filtration) to obtain a cell-free fluid that is then processed, typically using affinity media and/or enzymatic treatment. While such treatment is standard practice in many instances, hemolysis is often a problem. Still more disadvantageously, such known treatment typically requires relatively large equipment and is therefore impractical in ambulatory use.
- Further known methods for binding of a contaminant from a fluid are described in WO 2011/005742 where a sorbent medium is modified and combined with the fluid. However, the sorbent medium must be separated from cellular components, which is in most cases not feasible to the required degree. To assist in separation of the sorbent, magnetic beads can be used as is described in U.S. Pat. No. 6,143,510. However, such methods are generally limited to ex vivo tests as residual quantities of magnetic beads are highly undesirable. To circumvent problems associated with removal of sorbent, selective permeable membranes may be employed as taught in US 2009/0114595. While such removal is conceptually simple, separation efficiency is in at least some cases less than desirable, especially where large molecules are separated. Thus, there is still a need to provide improved whole blood separation devices and methods.
- The present inventive subject matter is directed to diagnostic and therapeutic devices in which whole blood is passed through one or more channels of a rotating or reciprocating element wherein the channels comprise an affinity agent to allow specific binding of a target compound to the channel. Due to the rotating or reciprocating motion of the element, the channel can be moved into and out of fluid communication with the circulatory system of a mammal such that the affinity agent binds the target compound when the channel is in fluid communication with the circulatory system and such that bound target antigen can be removed from the affinity agent when the channel is removed from the fluid communication with the circulatory system and in fluid communication with a regeneration circuit.
- In one aspect of the inventive subject matter, the rotating or reciprocating element has multiple channels and is configured as a rotating wheel, and multiple conduits are separately provided to the channels in the wheel to allow concurrent adsorption of the target compound to one channel while regenerating the affinity agent in another channel. Alternatively, the element may also be configured as an Archimedean screw or a reciprocating piston. Consequently, it should be recognized a target compound can be continuously removed from the blood stream on-line and in vivo as such devices and methods allow for multiple passes of whole blood through the device without saturating the affinity agent.
- Various objects, features, aspects and advantages of the present invention will become more apparent from the following detailed description of preferred embodiments of the invention.
- Most typically, contemplated devices will therefore include a first conduit, a second conduit, and a rotating or reciprocating element having a channel, wherein the first and second conduits are fluidly coupled to the rotating or reciprocating element such that the channel is fluidly continuous with the first conduit when the channel is fluidly discontinuous with the second conduit, and such that the channel is fluidly discontinuous with the first conduit when the channel is fluidly continuous with the second conduit. The first conduit is preferably configured to receive whole blood (directly from the circulation in an on-line mode, or indirectly, via blood collection bag or other implement), and the second conduit is preferably configured to receive a regeneration fluid (typically from a reservoir or device that prepares the regeneration fluid in situ). Regardless of the particular configuration, the channel will have a surface that is modified with an affinity agent (most typically an antibody or antibody fragment, a nucleic acid or nucleic acid analog, a lectin, etc.) at a concentration effective to allow removal of a target compound from whole blood, wherein the target compound is capable of binding with high specificity and affinity to the affinity agent.
-
FIG. 1A illustrates a whole blood treatment device including a wheel. -
FIG. 1B illustrates a whole blood treatment device including an Archimedean screw. -
FIG. 1C illustrates a whole blood treatment device including a reciprocating piston. -
FIG. 1A depicts an exemplary device in which the rotating or reciprocating element is configured as a wheel having a plurality of conduits extending through the wheel. The wheel is preferably rotatably coupled to at least two conduits, which are here indicated as half-pipes with abutting surfaces to so form a cylindrical structure. In the example ofFIG. 1A , the wheel is disposed in the middle of the conduits such that flow of whole blood enters the upper conduit at the site marked ‘whole blood inlet’, passes through the upper three channels that are coated with an antibody (e.g., specific against IL-8), and continues to flow through the upper half-pipe to exit at the site marked ‘whole blood outlet’. During this pass, target compounds will bind to the affinity agents. Similarly, and preferably at the same time, flow of regeneration fluid enters the lower conduit at the site marked ‘regen fluid inlet’, passes through the lower three channels and causes the bound target compounds to elute into the regeneration fluid, which flows through and exits the lower half-pipe to leave the pipe at the site marked ‘regen fluid outlet’. - It should be appreciated that the wheel will rotate during operation, preferably at a speed that will allow saturation of the affinity agents with the target compound during the presence of the channel in the upper half-pipe. Once saturated, and due to the preferably continuous rotation of the wheel, the channel with the saturated affinity agents will enter the lower half-pipe and is then exposed to the regeneration fluid for regeneration of the affinity agent. Once regenerated, and due to the preferably continuous rotation of the wheel, the channel with the regenerated affinity agents will enter the lower half-pipe and is once again available for a new cycle of binding and regeneration.
- Alternatively, and as depicted in
FIG. 1B , the rotating or reciprocating element is configured as a Archimedean screw that fittingly extends through the length of a cylindrical main pipe. At about the middle of the pipe, two fluid conduits join the main pipe in a manner such that (a) fluid entering on one branch of the main pipe is pumped along the pipe and exits one of the two joining conduits, and (b) fluid entering the other of the two joining conduits is pumped into and along the other branch and exits the other branch. In this example, the channel is formed by the helical groove of the screw and is also coated with (or otherwise coupled to) an affinity agent. Thus, in the example ofFIG. 1B , whole blood flows through one branch of the main pipe for adsorption of the target compound, while at the same time regeneration fluid flows through the other main branch for regeneration of the affinity agent. Flow of the whole blood and the regeneration fluid is then alternatingly controlled such that when the affinity agents are saturated in one branch, whole blood flow is routed to the other branch that is now regenerated. Regeneration fluid is then routed to the saturated channel to regenerate the binding surface. Viewed from a different perspective, the operational mode between binding and regeneration is switched by switching flow though the device. - Alternatively, the moving element may also be configured as a reciprocating piston with one or more channels extending through the piston as exemplarily illustrated in
FIG. 1C . Here, the piston has a plurality of channels where two channels are concurrently employed for binding and absorption. In this example, the regenerated channel is moved into the flow of whole blood as the binding channel is saturated.FIG. 1C shows an additional channel which may be employed for measurement of an analyte and/or dispensation of a pharmaceutical agent. Once more, it should be appreciated that binding and regeneration can be performed continuously and that such systems are particularly useful for continuous on-line separation of a target compound from whole blood. - Consequently, it should be recognized that method of removing a target compound from whole blood of a mammal is contemplated. More specifically, contemplated methods include a step of moving the whole blood through a channel in a rotating or reciprocating element while the channel is fluidly coupled to a first conduit that contains the whole blood, wherein the channel comprises a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood. In another step, the rotating or reciprocating element is moved into a position such that the channel is fluidly disconnected from the first conduit and fluidly connected with a second conduit, and in yet another step, the target compound is eluted from the surface while the channel is fluidly connected with the second conduit. The rotating or reciprocating element is then further moved into a position such that the channel is fluidly connected with the first conduit and fluidly disconnected with the second conduit.
- While it is in most aspects preferred that the affinity agent in contemplated devices and methods is continuously or intermittently regenerated, it should also be appreciated that the affinity agent may be saturated and then discarded (e.g., via user replacement of the rotating or reciprocating element, or via replacement of the channel where the channel is configured as a cylinder). Consequently, another embodiment of a whole blood treatment device may include a first conduit, a sealing area, and a rotating or reciprocating element having a channel, wherein the first conduit is fluidly coupled to the rotating or reciprocating element such that the channel is fluidly continuous with the first conduit when the channel is fluidly discontinuous with the sealing area, and such that the channel is fluidly discontinuous with the first conduit when the channel is fluidly continuous with the sealing area. In such devices, the first conduit is configured to receive whole blood, and the sealing area is configured to allow flow-less incubation of the whole blood in the channel when the channel is fluidly continuous with the sealing area. Thus, and viewed from a different perspective, a volume of whole blood is captured in the channel while the channel is in contact with the sealing area to so allow binding of a target compound from an essentially non-moving or non-flowing volume of whole blood. Such incubation is considered to improve binding efficiency, especially where the volume-to-surface ratio is relatively high. As noted before, the channel will include a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood. Where desirable, the rotating or reciprocating element is disposable and/or user-replaceable, and/or the channel is configured as a replaceable cylinder.
- Typical non-regenerating devices are similar to the devices shown in
FIG. 1A-1C , however, will not provide second conduits for regeneration fluid. For example, the second conduit in the device ofFIG. 1 is entirely omitted and a sealing plate or other sealing implement will seal off the lower conduit. Similarly, the Archimedean screw configuration ofFIG. 1B is simplified in that the perpendicular in- and outlet ports can be omitted. In such case, it is generally preferred that two linear conduits will have two independent Archimedean screws with one screw operating while the other screw is not operating and replaceable. Increased incubation time is then achieved by discontinuous rotation, or by addition of a second (third, or higher) screw that operates in a parallel and alternating mode. In the device ofFIG. 1C , the device configuration is again simplified by providing one or more flow channels through the reciprocating block. Reciprocating movement of the block will then position a volume of whole blood in a channel between sealing surfaces for a predetermined time to allow longer incubation, and reversal of that movement (or additional forward movement) will then move the treated volume back into circulation. - It is especially preferred that contemplated devices are configured to be wearable, and that the reciprocating or rotating element can be readily exchanged, preferably by a non-medical professional (e.g., end user or caretaker). Thus, in especially preferred aspects, the device has a housing that encloses at least partially the element and conduits. Fluid lines from the patient's circulation and/or regeneration fluid are preferably attachable via luer lock or other suitable connector that preferably allows maintaining sterile working conditions. Moreover, where the device is configured as a user-wearable device, the regeneration fluid (and other fluids, including wash fluids) are preferably also in a wearable format, and most preferably flexible pouches.
- In further preferred aspects of the inventive subject matter, it should be appreciated that the device may include more than one rotating or reciprocating element and/or that there are more than one type of affinity agent in one or more channels. Likewise, it should be recognized that contemplated devices and methods are not limited to those having only two conduits, but any number of conduits are deemed suitable. Additional conduits may be used for measurement of one or more analytes in the whole blood and/or the regeneration fluid, and/or for provision of wash fluids and/or pharmaceutical agent. Of course, contemplated device may also implement additional functionalities using a flow splitter that may be upstream or downstream, of the wheel (with respect to the flow of the whole blood). The so produced bypass or slipstream can then be treated or analyzed as desired, and fed back to the circulation or be discarded into a typically disposable waste container.
- While continuous flow of whole blood through the device is generally preferred, it is also contemplated that intermittent flow may be directed through the device. In such case, or where a stop valve is activated in the flow path, the conduit may include or may be coupled to a surge compartment to accommodate discontinuous flow and to maintain constant flow rate through the device. Thus, contemplated devices may have a continuously operating pump, a pump that operates in on-off mode, or no pump at all. Thus, the whole blood may be driven by an active pump (e.g., peristaltic, piston, etc.), or passively by a blood pressure driven mechanism. Similarly, it is generally preferred that the reciprocating or rotating element is actuated by a motor or other actuator, preferably in a continuous manner at constant speed. However, where desirable, the speed of the rotating or reciprocating element may also be variable and/or in an intermittent pattern.
- The number and geometry of channel may vary considerably and will predominantly be determined by the desired flow rate of whole blood through the element, the quantity of target compound in the whole blood, and affinity of the target compound. It is generally preferred that the channels are formed to reduce or even entirely avoid turbulent flow. Thus, channels are preferably linear or helical with a larger-than-capillary diameter (e.g., at least 50 micron, more preferably at least 100 micron, and most preferably at least 250 micron). It is further noted that the transition of a channel from blood to regeneration fluid may include a rinse step in the device and/or via a flow loop with one or more valves. Thus, most preferably, loss of whole blood is avoided as the volume of whole blood in the channel may be recycled back to the mammal (e.g., using isotonic fluid as a wash fluid).
- Sealing of the movable element against fluid and blood loss can be achieved in numerous manners well known in the art. For example, rotary seals, rubber lip seals, or bore seals with 0-rings are deemed suitable for use herein. Similarly, press-fit tolerance may be employed to reduce leakage of the channel/conduit interface.
- Many various target compounds can be targeted for removal from the blood, and various affinity agents can be used, where the affinity agents have a binding affinity to the target compound to be removed. The inventors have now discovered that chemotherapy compliance can be significantly improved when IL-8 and/or CRP concentrations are reduced in whole blood of a patient that is treated with a drug that increases at least one of IL-8 and/or CRP. In especially preferred aspects, IL-8/CRP reduction is performed on-line in a continuous manner using a wearable device, such as the device described herein. The device can be used to remove other antigens and small molecules from whole blood by passing the blood through channels, which comprise an affinity agent to bind to the target compound.
- In one particularly preferred aspect of the inventive subject matter, IL-8 and CRP levels are elevated in whole blood of a patient undergoing taxane (e.g., paclitaxel or decetaxel) chemotherapy, for example, in the treatment of pancreatic cancer. Such treatment may be in combination with other drugs, for example, gemzitabine. Most typically, chemotherapy in such and similar cases is not well tolerated and a significant fraction of patients will discontinue treatment due to the severe side effects.
- The inventors have determined that IL-8 and CRP levels in patients about to discontinue chemotherapy is well above normal reference ranges, typically at least 25%, and most typically at least 50% above the upper range of normal, and contemplate that continuous reduction of the elevated levels, preferably back to reference range, will increase the level of compliance. It is generally preferred that the continuous treatment will extend over a period of at least 12 hours, more typically at least 24 hours, and most typically over at least 3 days. Thus, and viewed from another perspective, it is contemplated that the reduction of IL-8 and/or CRP will be effected over a period that coincides with at least a portion of time over which elevated levels will be observed without treatment.
- In this context, it should be noted that the reduction of IL-8 and/or CRP is not intended as a treatment modality of the underlying disease, but as a palliative treatment of a condition that is brought about by pharmacological intervention. Thus, methods presented herein are targeted to improve subjective well-being of a patient, and especially relieve nausea, flu-like symptoms, loss of appetite, and physical and/or metal fatigue.
- However, and with respect to the disease being treated, it should be appreciated that any disease that requires drug treatment, and/or any disease that is characterized by excessive blood concentrations of IL-8 and/or CRP is contemplated herein. For example, contemplated methods may be effective not only in combating side effects of chemotherapy of various neoplastic diseases, but also infectious diseases and especially including viral diseases (and particularly influenza virus, H1N1 flu, SARS, etc.), chronic inflammatory diseases (e.g., COPD, rheumatoid arthritis, inflammatory bowel disease, psoriasis, etc.), atherosclerosis, and acute coronary syndrome.
- Consequently, and depending on the particular nature of disease or treatment, it should be appreciated that the chemotherapeutic agent may vary considerably. Most typically, however, the pharmaceutical treatment will include chemotherapy for various neoplastic diseases, and especially those agents that are known to be associated with an increase in IL-8 and/or CRP. For example, contemplated chemotherapies may include administration of one or more of receptor antibodies, alkylating agents, antimetabolites, microtubule inhibitors (and especially taxanes), topoisomerases, and kinase inhibitors. Similarly, contemplated methods may be implemented on an intermittent or continuous basis, and it is generally contemplated that the reduction in IL-8 and/or CRP is performed as long as excessive levels of IL-8 and/or CRP are measured or anticipated. For example, where administration of a chemotherapeutic agent results in a relatively broad and temporary spike in blood IL-8 levels (e.g., over 2 days), reduction of IL-8 may be performed in a continuous manner over two days. On the other hand, where the increase is relatively brief, reduction may be performed in a discontinuous manner immediately following administration of the chemotherapeutic agent. On the other hand, where the elevated levels of IL-8 and/or CRP are, for example, due to a chronic inflammatory condition, continuous reduction in IL-8 and/or CRP may be advisable.
- Removal is preferably monitored to achieve a continuous IL-8 and/or CRP level that is within the normal reference range (and in some cases below or slightly above). For example, the clinical range of IL-8 is typically between 10-80 pg/ml for a healthy person, and it is typically preferred that reduction of IL-8 is to equal or less than 100 pg/ml, and more preferably to equal or less than 80 pg/ml. Similarly, the clinical normal range for CRP is between 0-5 mg/l for male and 0-8 for female healthy adults, and it is typically preferred that reduction of CRP is to equal or less than 5 mg/1, more preferably to equal or less than 3 mg/l, and most preferably to equal or less than 1 mg/l.
- Reduction of IL-8 and/or CRP is preferably effected via specific antibodies (e.g., HuMab 10F8 for IL-8), or other known IL-8 binders, including glycosaminoglycan (GAG) heparin, protease inhibitor alpha2-macroglobulin, Cyclosporin A, however, engineered binding agents are also deemed suitable, including recombinant IL-8 receptor and fragments thereof. Similarly, it is contemplated that CRP can be reduced by binding of CRP to one or more types of monoclonal or polyclonal antibodies, Fc receptors (e.g., FcγRIIa), etc., and the number of binding agents needed to reduce the IL-8 and/or CRP levels will preferably be chosen such that continuous treatment for at least 2, and more typically 4 consecutive days is possible without patient intervention.
- The device may also be used to target other cellular components and extracellular components, such as proteins, fats and small molecules, and may also be used to target cells. The whole blood treatment device can also be used to treat various diseases that are caused by one or more target compounds. Examples of these disease include treating cancer by reducing inhibitory checkpoint molecules or removing cancer cells, autoimmune diseases by reducing inflammatory factors, cardiovascular disease by reducing low-density lipoprotein, metabolic diseases such as diabetes by reducing glucose, viral infection and bacterial infection by reducing the amount of virus, bacteria or associated toxin, and toxin exposure and heavy metal exposure by removing the toxin or heavy metal. Such diseases may be treated with the device by determining a target compound that can be removed from the body, and determining an affinity agent that binds to the target compound. Antibodies or aptamers suited to binding the selected target compound could be used as the affinity agents, but it is understood that other compounds could also be used.
- Inhibitory checkpoint molecules are secreted by cancer cells to reduce the immune response. There are several antibody drugs (referred to as immune checkpoint inhibitors or immune checkpoint blockades) that target these inhibitory checkpoint molecules in order to increase the immune response to cancer cells. Rather than using these antibodies as a drug, the whole blood treatment devices pass whole blood through channels with a surface modified with affinity agents, where the inhibitory checkpoint molecules are bound by the affinity agents, and removed from the blood, reducing the concentration of inhibitory checkpoint molecules in the blood. Some examples of inhibitory checkpoint molecules are cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), programmed death-ligand 1 (PD-L1), B7-1, B7-2, FOXP3+, FOXP3−, Treg 17, Trl, Th3, IL-10, and TGF-β. Some examples of antibody drugs that could be used as affinity agents include ipilimumab, ticilimumab, pembrolizumab, atezolizumab and nivolumab, along with many others, as described in Ghirelli et al. (“Targeting immunosuppression for cancer therapy” J Clin Invest. 2013; 123(6):2355-2357).
- Inflammatory factors are often reduced using antibody drug treatments. Rather than administering antibodies as drugs, these same antibodies can be used in the channels of the whole blood treatment devices to bind inflammatory factors to reduce the concentration of inflammatory factors in the blood. Inflammatory factors may include IL-4, IL-10, TNFα, IL-17A, IL-17F, CRP, TNF, IL-1α, IL-1β, IL-5, IL-6, IL-8, IL-12, IL-23, CD2, CD3, CD20, CD22, CD52, CD80, CD86, C5 complement protein, BAFF, APRIL, IgE, α4β1 integrin and α4β7 integrin. These inflammatory factors may be bound by IL-17A/F antibodies, abatacept, alefacept, alemtuzumab, atacicept, belimumab, canakinumab, eculizumab, epratuzumab, natalizumab, ocrelizumab, ofatumumab, omalizumab, otelixizumab, rituximab, teplizumab, vedolizumab, adalimumab, briakinumab, certolizumab pegol, etanercept, golimumab, infliximab, mepolizumab, reslizumab, tocilizumab and ustekinumab. Other antibodies or aptamers could also be used to target inflammatory factors as shown in Focosi et al. (“Immunosuppressive monoclonal antibodies: current and next generation” Clin Microbiol Infect 2011; 17: 1759-1768) and Chan, A. C. et al. (“Therapeutic antibodies for autoimmunity and inflammation”, Nature Reviews Immunology, vol. 10, pp. 301-316, (2010)). Diseases that could be treated by targeting inflammatory factors include asthma, rheumatoid arthritis, autoimmune disorders and gastrointestinal diseases.
- Viruses can be targeted using various drugs. However, removing these from the blood, via a whole blood treatment device would reduce unintended side effects. The target compounds can include viruses and cells infected with viruses. Examples of viruses include chickenpox, flu (influenza), herpes, human immunodeficiency virus (HIV/AIDS), human papillomavirus (HPV), infectious mononucleosis, mumps, measles, rubella and shingles. Antibodies that bind to these viruses may be used as the affinity agent, and can be prepared by well-known methods.
- Antibodies can be used to treat various cancers. Rather than using antibodies that bind cancer cells as a drug, these antibodies can be used in a channel of a whole blood treatment device. Examples of cancer cells include skin, breast, lung, pancreas, kidney, leukemia, lymphoma, and many other types of cancer. For example, treatment of cancer can be carried out by targeting cells displaying nucleolin on the cell surface. Anti-nucleolin antibodies can bind to the nucleolin on the surface of the cancer cell. Various anti-nucleolin antibodies include p7-1A4 mouse monoclonal antibody, sc-8031 mouse mAb, sc-9893 goat polyclonal Ab (pAb), sc-9892 goat pAb, clone 4E2 mouse mAb, and clone 3G4B2 mouse mAb, which may be used as affinity agents. Other examples of antibody drugs to treat cancer cells, which may be used as affinity agents include alemtuzumab, trastuzumab, Ibritumomab tiuxetan, Brentuximab vedotin, Ado-trastuzumab emtansine, denileukin diftitox, and blinatumomab, along with other can be found in American Cancer Society; Monoclonal Antibodies to Treat Cancer (available at www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/monoclonal-antibodies.html). Other drugs may be used to bind cancer cells within the device.
- Heavy metal poisoning may be treated with a whole blood treatment device to reduce the concentration of heavy metals to a safe level. Heavy metals may include lead, mercury, arsenic and cadmium. These metals can be bound by an affinity agent such as DNAzyme as described in Zhang et al. (“Metal Ion Sensors Based on DNAzymes and Related DNA Molecules” Annual review of analytical chemistry 2011; 4(1):105-128). Chelating agents could also be used as an affinity agent to bind to the target compounds in the device.
- Alzheimer's disease can be treated with solanezumab. Rather than administering this drug to a patient, a whole blood treatment device can be used to filter target compounds from whole blood, using the antibody as an affinity agent. Some examples of target compounds for Alzheimer's disease include misfolded amyloid beta and tau proteins.
- Bacteria and toxins in the bloodstream can be treated with various drugs. Rather than administering these drugs to a patient, a whole blood treatment device can be used to filter the bacteria or toxins from whole blood. Examples of toxins which could be target compounds include botulinum toxin produced by Clostridium botulinum, Corynebacterium diphtheriae toxin, produced during life-threatening symptoms of diphtheria, and tetanospasmin produced by Clostridium tetani. Antibodies and aptamers may be used as affinity agents for the bacteria or toxins. Such antibodies and aptamers may be prepared by well-known methods.
- Various potent cytokines, including tumor necrosis factor (TNF) and
interleukin 1, are at increased concentrations in the blood of patients with sepsis. Furthermore, inhibitory checkpoint molecules are also present in increased concentration in the blood of patients with sepsis. These are described in Hotchkiss et al. (“Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach” The Lancet infectious diseases. 2013; 13(3):260-268). A whole blood treatment device can be used to filter the cytokines or inhibitory checkpoint molecules from whole blood. Antibodies and aptamers may be used as affinity agents for the bacteria or toxins. - Methanol poisoning can be treated by competitive inhibition. Methanol concentration could also be reduced using the whole blood treatment device with affinity agents such as aptamers.
- Heroin overdoses can be treated by various drugs. Rather than administering these drugs, a whole blood treatment device could be used to reduce the concentration of opioids in the blood. Antibodies, aptamers or other compounds may be used as affinity agents for the opioids.
- Methods of making antibodies are well-known in the art. Monoclonal antibodies are usually made by fusing mouse spleen cells immunized with a desired antigen with myeloma cells (B-cell cancer cells, which are known for producing antibodies). The fused cells are transferred to a medium that is selective for fused cells. Several cell cultures are then grown from single parent cells. The antibodies from the different parent cells are then assayed using well-known methods such as ELISA to determine the antibodies ability to bind the antigen.
- It would be understood by those skilled in the art, that the systematic evolution of ligands by exponential enrichment (SELEX) technique, or similar techniques, could be used to produce aptamers that specifically bind or target compounds or cells. In the SELEX technique, a large quantity of randomly generated sequences is generated and exposed to the target ligand. The sequences that did not bind the target ligand are removed through affinity chromatography. The sequences that did bind the target ligand are then eluted and amplified by PCR to prepare for subsequent rounds of selection, in order to find the sequence that binds best to the ligand.
Claims (28)
1-13. (canceled)
14. A method of removing a target compound from whole blood of a mammal in a whole blood treatment device, comprising:
(a) moving the whole blood through a channel in a rotating or reciprocating element while the channel is fluidly coupled to a first conduit that contains the whole blood;
wherein the channel comprises a surface that is modified with an affinity agent at a concentration effective to allow removal of a target compound from whole blood;
(b) moving the rotating or reciprocating element in a position such that the channel is fluidly disconnected from the first conduit and fluidly connected with a second conduit;
(c) eluting the target compound from the surface while the channel is fluidly connected with the second conduit; and
(d) further moving the rotating or reciprocating element in a position such that the channel is fluidly connected with the first conduit and fluidly disconnected with the second conduit,
wherein the rotating or reciprocating element is selected from the group consisting of a wheel, an Archimedean screw and a reciprocating piston.
15-17. (canceled)
18. The method of claim 14 wherein the rotating or reciprocating element further comprises a third conduit that is fluidly coupled to an analyzer, and further comprising a step of using the analyzer to measure a quantity of an analyte in the whole blood or eluate.
19. The method of claim 14 wherein the rotating or reciprocating element further comprises a fourth conduit that is fluidly coupled to a dispensing device, and further comprising a step of using the dispensing device to dispense a measured quantity of a pharmaceutical agent into the whole blood.
20. The method of claim 14 wherein the steps (a)-(d) are performed while the mammal wears the device on the body.
21-22. (canceled)
23. A method of palliative treatment of a patient, comprising:
ascertaining that at least one of an IL-8 level and a CRP level is elevated above normal as a consequence of a disorder or pharmaceutical intervention; and
continuously reducing at least one of IL-8 and CRP in whole blood of the patient using the device of claim 1 that is configured to bind at least one of IL-8 and CRP.
24. The method of claim 23 wherein the IL-8 level and the CRP level are elevated.
25. The method of claim 23 wherein the at least one of the IL-8 level and the CRP are elevated as a consequence of pharmaceutical intervention.
26. The method of claim 25 wherein the pharmaceutical intervention is a chemotherapy for treatment of a neoplastic disease.
27. The method of claim 23 wherein the disorder is a chronic inflammatory disease.
28. The method of claim 23 wherein the at least one of the IL-8 and the CRP are reduced to normal reference level.
29-41. (canceled)
42. The method of claim 14 , wherein the affinity agent is selected from the group consisting of antibodies, aptamers and small molecules.
43. The method of claim 14 , wherein the target compound is IL-8.
44. The method of claim 43 , wherein the affinity agent is selected from the group consisting of: HuMab 10F8, glycosaminoglycan (GAG) heparin, protease inhibitor alpha2-macroglobulin and Cyclosporin A.
45. (canceled)
46. The method of claim 14 , wherein the target compound is CRP.
47. (canceled)
48. The method of claim 14 , wherein the target compound is selected from the group consisting of: cellular components, extracellular components, and cells.
49. The method of claim 14 , wherein the target compound is an inhibitory checkpoint molecule.
50. The method of claim 14 , wherein the target compound is an inflammatory factor.
51. The method of claim 14 , wherein the target compound is cancerous cells.
52. The method of claim 51 , wherein the affinity agent is an anti-nucleolin antibody.
53. The method of claim 14 , wherein the target compound is selected from the group consisting of: viruses, bacteria and toxins.
54. (canceled)
55. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/918,494 US20200397985A1 (en) | 2017-03-06 | 2020-07-01 | Devices and methods for on-line whole blood treatment |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762467408P | 2017-03-06 | 2017-03-06 | |
US15/913,729 US10744258B1 (en) | 2017-03-06 | 2018-03-06 | Devices and methods for on-line whole blood treatment |
US16/918,494 US20200397985A1 (en) | 2017-03-06 | 2020-07-01 | Devices and methods for on-line whole blood treatment |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/913,729 Continuation US10744258B1 (en) | 2017-03-06 | 2018-03-06 | Devices and methods for on-line whole blood treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200397985A1 true US20200397985A1 (en) | 2020-12-24 |
Family
ID=72045783
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/913,729 Active 2038-12-24 US10744258B1 (en) | 2017-03-06 | 2018-03-06 | Devices and methods for on-line whole blood treatment |
US16/918,494 Pending US20200397985A1 (en) | 2017-03-06 | 2020-07-01 | Devices and methods for on-line whole blood treatment |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/913,729 Active 2038-12-24 US10744258B1 (en) | 2017-03-06 | 2018-03-06 | Devices and methods for on-line whole blood treatment |
Country Status (1)
Country | Link |
---|---|
US (2) | US10744258B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USD952157S1 (en) | 2020-06-19 | 2022-05-17 | Qualigen Inc. | Whole blood treatment cartridge |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10744258B1 (en) * | 2017-03-06 | 2020-08-18 | Qualigen Inc. | Devices and methods for on-line whole blood treatment |
WO2021262147A1 (en) * | 2020-06-23 | 2021-12-30 | Qualigen Inc. | Devices and methods for on-line whole blood treatment |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090114595A1 (en) * | 2005-02-16 | 2009-05-07 | Triomed Ab | System and Method for Regeneration of a Fluid |
US10744258B1 (en) * | 2017-03-06 | 2020-08-18 | Qualigen Inc. | Devices and methods for on-line whole blood treatment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69534294T2 (en) | 1994-07-29 | 2006-05-18 | Mitsubishi Kagaku Iatron, Inc. | MEASURING SYSTEM USING FULL BLOOD |
US7214544B2 (en) | 1999-03-02 | 2007-05-08 | Qualigen, Inc. | Semi-continuous blood separation using magnetic beads |
CN102648045A (en) | 2009-07-06 | 2012-08-22 | 马尔系统公司 | Media for removal of contaminants from fluid streams and method of making and using same |
-
2018
- 2018-03-06 US US15/913,729 patent/US10744258B1/en active Active
-
2020
- 2020-07-01 US US16/918,494 patent/US20200397985A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090114595A1 (en) * | 2005-02-16 | 2009-05-07 | Triomed Ab | System and Method for Regeneration of a Fluid |
US10744258B1 (en) * | 2017-03-06 | 2020-08-18 | Qualigen Inc. | Devices and methods for on-line whole blood treatment |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USD952157S1 (en) | 2020-06-19 | 2022-05-17 | Qualigen Inc. | Whole blood treatment cartridge |
Also Published As
Publication number | Publication date |
---|---|
US10744258B1 (en) | 2020-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200397985A1 (en) | Devices and methods for on-line whole blood treatment | |
AU2009227872B2 (en) | Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients | |
EP0111696A2 (en) | An arrangement for the removal of one or more fractions out of whole blood, plasma or other similar body fluids | |
US20220143291A1 (en) | Whole blood treatment device and methods of removing target agents from whole blood | |
AU2022203249B2 (en) | System and method for removal of immune inhibitors from biological fluids | |
WO2021262147A1 (en) | Devices and methods for on-line whole blood treatment | |
CN114502210A (en) | Assembly for extracorporeal treatment of body fluids | |
Pták | Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis | |
US11123467B2 (en) | System and method for removal of immune inhibitors from biological fluids | |
JP2011036128A (en) | Method for producing antibody | |
JP2023513684A (en) | Use of Alkaline Hydroxide Solution for Regeneration of Apheresis Columns | |
TWI762833B (en) | System and method for removal of immune inhibitors from biological fluids | |
US20230321412A1 (en) | System and method for managing cancer cells in csf | |
EP4374876A2 (en) | Method for generating immunoregulatory cells in a blood-derived sample | |
Horton et al. | The use of therapeutic apheresis in allergic and immunological diseases | |
JP2006346096A (en) | Base material for blood processing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |